Olaparib gets UK’s approval for ovarian cancer

27 Jan 2016

UK’s regulatory body NICE (The National Institute for Health and Care Excellence) has recommended olaparib (also known as Lynparza) for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube and peritoneal cancer.

The drug is for cancers in adults who have been tested positive for the BRCA1 or BRCA2 mutations, and whose disease has responded to platinum-based chemotherapy.

CareAcross-chemistry

What are the recommendations for olaparib?

Specifically, the recommendations say that olaparib should be available for people only if they have had 3 or more courses of platinum-based chemotherapy and the drug cost of olaparib for people who remain on treatment after 15 months is met by the company.

The drug is manufactured by AstraZeneca.

Source: eCancer News

Login to your account

Did you forget your password?